C4 Therapeutics Stock (NASDAQ: CCCC) stock price, news, charts, stock research, profile.
Open | $6.820 |
Close | $6.860 |
Volume / Avg. | 746.871K / 2.673M |
Day Range | 6.700 - 7.000 |
52 Wk Range | 1.060 - 11.880 |
Market Cap | $479.519M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 41 |
Short Interest | 18.92% |
Days to Cover | 5.18 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of C4 Therapeutics (NASDAQ: CCCC) through any online brokerage.
Other companies in C4 Therapeutics’s space includes: Skye Bioscience (NASDAQ:SKYE), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV), Valneva (NASDAQ:VALN) and Celcuity (NASDAQ:CELC).
The latest price target for C4 Therapeutics (NASDAQ: CCCC) was reported by Morgan Stanley on Monday, February 26, 2024. The analyst firm set a price target for 8.00 expecting CCCC to rise to within 12 months (a possible 14.45% upside). 12 analyst firms have reported ratings in the last year.
The stock price for C4 Therapeutics (NASDAQ: CCCC) is $6.99 last updated April 22, 2024 at 6:42 PM EDT.
There are no upcoming dividends for C4 Therapeutics.
C4 Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for C4 Therapeutics.
C4 Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.